BPA, chemically known as 2,2-bis(4-hydroxyphenyl) propane, is a workhorse of industrial chemistry. It forms the backbone of polycarbonate plastics and epoxy resins and lurks in food packaging linings, metal cans, water bottles, electronic devices, toys, and medical equipment. Because its molecular structure features two phenolic rings resembling those of the hormone estradiol, BPA can mimic estrogenic activity in the body. The bonds holding BPA within polymerized resins are flexible enough that acidic or basic conditions and elevated temperatures liberate the compound, allowing it to migrate into food and drink. As a lipophilic molecule, it enters the body through mucous membranes, the respiratory tract, and skin, most often via the food chain.

The consequences of this ubiquitous exposure are far from trivial. BPA has been detected in breast milk, ovarian follicular fluid, amniotic fluid, umbilical cord blood, and placental tissues, indicating that humans are exposed from before birth onward. Research has linked the compound to elevated free radical production, disrupted meiosis, oocyte degeneration, and impaired ovarian function. The ovary is particularly vulnerable to oxidative stress, which can derail steroidogenesis, damage follicles, and degrade ovarian tissue. Prior studies have shown that BPA lowers estradiol levels, reduces the numbers of antral and primary follicles and corpora lutea, and promotes apoptotic changes in granulosa cells that may prevent ovulation altogether.

Enter quinoa, the Andean pseudocereal once revered as the mother of grains by the Incas and now celebrated globally as a superfood. Beyond its exceptional protein content and balanced amino acid profile, quinoa carries a pharmacological portfolio that includes antimicrobial, antioxidant, immunomodulatory, antidiabetic, neuroprotective, and hepatoprotective effects. Its seeds contain terpenoids, steroids, phenolic acids, and flavonoids with demonstrated anti-inflammatory, anticancer, and antidepressant potential. Earlier work had shown that quinoa seed powder could protect female rats against reproductive damage from the chemotherapy drug cisplatin, but no one had tested the seed extract against BPA-induced ovarian injury until now.

The research team, led by Pijus Kanti Jana and corresponding author Sandip Chattopadhyay, first characterized their hydroethanolic quinoa seed extract using liquid chromatography coupled with mass spectrometry. The analysis revealed four prominent phytochemical peaks: gallic acid, the most abundant compound at 170.76 mass-to-charge ratio, followed by caffeic acid, quercetin, and a 5-n-nonadecylresorcinol derivative. These molecules would prove central to the story, as each carries documented antioxidant, anti-inflammatory, or phytoestrogenic credentials that map neatly onto the damage pathways BPA exploits.

For the experiment itself, twenty-four virgin female Wistar albino rats, aged six to seven weeks, were randomly divided into four groups of six. Over twenty-eight consecutive days, the animals received daily oral gavage: a control group received olive oil alone, a positive control received quinoa ethanolic extract at 400 milligrams per kilogram of body weight, a BPA group received the chemical at 100 milligrams per kilogram, and a combined group received both BPA and the extract. The team monitored estrous cycles daily through vaginal smears, then on day twenty-nine collected serum and organs for an exhaustive battery of biochemical, molecular, and histological assays, all conducted under institutional ethics approval.

The results were striking across every measure. Rats exposed to BPA alone showed disrupted estrous cycles dominated by persistent metestrus and diestrus, significantly reduced serum estradiol and progesterone, diminished expression of the steroidogenic enzymes 3-beta-hydroxysteroid dehydrogenase and aromatase, and depleted estrogen receptor-alpha signaling. Their ovaries harbored arrested follicular growth and atretic follicles, and their relative ovarian weight dropped significantly. Antioxidant enzymes, including superoxide dismutase, catalase, and glutathione peroxidase, were sharply suppressed, while lipid peroxidation markers malondialdehyde and conjugated dienes surged and lactate dehydrogenase leaked into the serum, a signature of cellular membrane damage and necrosis.

Coadministration of the quinoa extract reversed nearly all of this damage. Treated rats regained more regular estrous cycles, normalized hormone levels, and restored expression of ER-alpha, 3-beta-HSD, and aromatase. Antioxidant enzyme activity and expression rebounded, lipid peroxidation fell dramatically, and serum LDH declined, indicating protection from tissue necrosis. The inflammatory cascade also quieted: ovarian levels of TNF-alpha, NF-kappa-B, and IL-6, all significantly elevated by BPA, dropped toward baseline after quinoa supplementation. At the transcript level, BPA had boosted proapoptotic genes p53 and BAX while suppressing the antiapoptotic Bcl-2, an imbalance signaling cell cycle arrest and programmed cell death; quinoa co-treatment corrected this ratio. Under the microscope, ovaries from the combined group showed a predominance of normally developing follicles and far fewer atretic structures than the BPA-only group.

The authors attribute these protective effects to the specific phytochemicals identified in the extract. Quercetin, a phytoestrogen, can interact with estrogen receptors to improve estrogen and progesterone levels, while resorcinol engages helix 3 of ER-alpha through hydrogen bonding, exerting partial agonistic activity that helps restore estradiol signaling. On the antioxidant front, resorcinol activates Nrf2-mediated signaling, and gallic acid and quercetin raise cellular glutathione, scavenging reactive oxygen species before they can peroxidize cell membranes. Gallic acid also inhibits phosphorylation of I-kappa-B kinase, blocking NF-kappa-B nuclear translocation and the ensuing cytokine storm, while quercetin suppresses MAPK and downstream NF-kappa-B signaling and caffeic acid downregulates the TLR4/MyD88 pathway. Together, these molecules intercept BPA’s damage at the estrogenic, oxidative, inflammatory, and apoptotic levels simultaneously.

The researchers caution that this is a preliminary in vivo study in rats, and the doses involved, particularly the 100 milligrams per kilogram BPA exposure, far exceed typical human intake. Translating these findings into dietary recommendations for women will require dose-ranging work, pharmacokinetic data, and ultimately human studies. Still, the concept is tantalizing: a widely available, nutrient-dense seed whose bioactive compounds appear to fortify the ovary against one of the most pervasive contaminants of the industrial age. As concerns over endocrine disruptors continue to mount, quinoa’s journey from ancient Incan staple to potential protective nutraceutical offers a vivid reminder that sometimes the tools for fighting modern chemical hazards may have been growing in the Andes all along.

Subject of Research: Protective effects of quinoa seed extract against bisphenol A-induced ovarian toxicity in female rats

Article Title: Exploring the protective effects of ethanolic extract of Chenopodium quinoa seed (quinoa) on the reproductive alterations of BPA-exposed females in vivo: a preliminary study

Article References: Jana, P. K., Sil, S., Ghosh, A., Sultana, I., & Chattopadhyay, S. (2025). Exploring the protective effects of ethanolic extract of Chenopodium quinoa seed (quinoa) on the reproductive alterations of BPA-exposed females in vivo: a preliminary study. Discover Toxicology, 2(1), Article 7. https://doi.org/10.1007/s44339-025-00023-z

Image Credits: AI Generated

DOI: 10.1007/s44339-025-00023-z

Keywords: bisphenol A, quinoa, ovarian toxicity, endocrine disruptors, oxidative stress, phytoestrogens, gallic acid, quercetin, reproductive health, antioxidants, Wistar rats, steroidogenesis

Phytoestrogens are secondary metabolites that plants use for their own purposes, defending against disease and herbivores, supporting reproduction, and even coloring flowers. Chemically, they are defined by two hydroxyl groups attached to a phenolic ring, a structure close enough to 17β-estradiol that the phenolic group can bind to estrogen receptors in animals, acting as either an agonist or an antagonist. The most common forms in plants are conjugated glycosides, which are biologically inactive until gut bacteria and intestinal enzymes cleave the sugar groups, making bioavailability dependent on each species’ digestive machinery. Once absorbed, phytoestrogens are conjugated in the liver, circulate in the bloodstream, and are eventually excreted in urine.

The review organizes these compounds into two broad chemical families. Flavonoids, built on a diphenyl propane skeleton of two benzene rings closed by a heterocyclic pyran ring, include isoflavones such as genistein, daidzein, biochanin A, and formononetin; flavones such as luteolin and apigenin; and coumestans, of which coumestrol is the standout. Non-flavonoids comprise the stilbenes, including resveratrol, and the lignans, which gut metabolism converts into enterodiol and enterolactone. Coumestrol is particularly potent, showing 30 to 100 times the estrogenic activity of isoflavones because its two hydroxyl groups sit in positions matching those of estradiol, allowing it to inhibit key steroidogenic enzymes such as aromatase and 3-hydroxysteroid dehydrogenase.

Legumes are the richest sources, with many feed legumes containing phytoestrogens at 5 to 25 percent of their composition. In soybeans, genistein and daidzein together account for up to 90 percent of isoflavones, while red clover is dominated by formononetin and biochanin A. Concentrations vary with temperature, humidity, light, plant age, fertilization, and infection, and different compounds accumulate in different plant parts. Flax and sesame seeds are the most abundant lignan sources, coumestans concentrate in sprouts and fodder crops, and phytosterols such as sitosterol appear in plant oils and even in pulp mill effluents at levels with biological effects. Algae, cyanobacteria, and aquatic macrophytes may add further phytoestrogens to aquatic ecosystems, though their significance remains poorly quantified.

At the right doses, phytoestrogens can genuinely help farmed fish. Low concentrations of genistein enhanced growth in goldfish and yellow perch by modulating the growth hormone and insulin-like growth factor I axis. Their polyphenolic structure gives them antioxidant properties, scavenging free radicals and reducing oxidative stress. Moderate intake has been linked to enhanced lysozyme activity and leukocyte function, and equol, a metabolite of daidzein, promoted ovarian development and fecundity in female beluga sturgeon. Phytoestrogens can also induce vitellogenin synthesis in fish hepatocytes, hinting at potential as natural alternatives to synthetic hormones in reproductive management.

The darker side emerges when exposure is high or prolonged. As xenoestrogens, phytoestrogens bioaccumulate in fish tissues and drive reproductive abnormalities: male fish produce aberrant vitellogenin and show reduced sperm counts, while females suffer lower fecundity and egg hatchability. In rainbow trout, elevated dietary phytoestrogens impaired lipid metabolism and caused excess fat accumulation in hypertrophic adipocytes, threatening product quality. Estradiol-like signaling downregulates the GH/IGF axis in salmonids, boosting protein degradation and suppressing protein synthesis in muscle, and phytoestrogens such as genistein and daidzein slowed protein synthesis in trout muscle cells. High dietary soy isoflavones significantly reduced weight gain, feed efficiency, and whole-body lipid content in Japanese flounder. Immunity can also suffer: in beluga sturgeon, dietary phytoestrogens reduced lysozyme and IgM concentrations, echoing mammalian findings where genistein shrank the thymus in mice.

Reproductive disruption is the most dramatic effect. Genistein inhibits ovarian aromatase expression while raising serum testosterone and estradiol, yet reduced estrogen receptor expression means vitellogenin production falls, leaving female common carp with smaller, less vitellogenic ovaries. In channel catfish, chronic dietary genistein at 4 and 8 milligrams per gram produced more phenotypic males and intersex individuals, likely because the compound both mimics and blocks estrogen by inhibiting aromatase. Sperm quality is vulnerable too: genistein-enriched diets reduced sperm motility and concentration in rainbow trout in a dose-dependent manner, and in vitro genistein exposure cut sperm motility, ATP content, and fertilization rates in channel catfish and walleye. Yet the picture is not uniform. In fighting fish, waterborne genistein and β-sitosterol had no effect on sperm quality, and soy protein concentrate showed no estrogenic effect on trout juveniles.

These contradictions reflect a deeper truth the review emphasizes: responses are intensely species-specific. Carnivorous sturgeon metabolize phytoestrogens slowly, so the compounds accumulate in tissues and perturb sex differentiation, while omnivorous common carp show more moderate responses, likely thanks to metabolic adaptability. Aromatase inhibition by phytoestrogens varies across species, tissues, and developmental stages, and even within a species, individuals differ by sex, age, and genetic background in the expression of metabolic enzymes such as cytochrome P450s. The authors point to striking parallels beyond fish: Southern White Rhinoceroses show marked estrogen receptor activation on phytoestrogen exposure that their one-horned relatives do not, a difference implicated in captive breeding failures.

Fortunately, mitigation is feasible. Extensive pre-cooking before crushing removes 50 to 80 percent of the initial isoflavone content of soy products, soaking and boiling leach daidzein and genistein into water, and heating triggers Maillard-type reactions and auto-degradation that lower genistein levels. Growing soybeans at higher temperatures reduces isoflavone accumulation. Enzymatic treatments using laccases and peroxidases can degrade isoflavones and lignans into less bioavailable forms, lactic acid bacteria fermentation modifies genistein and daidzein during processing, and selective breeding is producing low-phytoestrogen soy, clover, and legume cultivars without sacrificing yield. Alternative plant proteins such as pea, lupine, and beans carry lower phytoestrogen loads.

The review closes with a regulatory warning. While the fungal mycoestrogen zearalenone has guidance values in livestock feed, ranging from 0.1 to 0.5 milligrams per kilogram under European Commission Recommendation 2006/576/EC, no such thresholds exist for naturally occurring phytoestrogens in aquafeeds, despite teleost fish being especially sensitive to hormonal perturbation during early development and gonadal differentiation. The authors call for species-specific toxicological studies, dose-response relationships, and maximum residue limits tailored to aquaculture, alongside long-term exposure research and ecological assessments of farm effluents, which can carry phytoestrogens into wild fish populations. As plant-based feeds become the backbone of sustainable aquaculture, managing these invisible hormones may prove as important as the protein itself.

Subject of Research: Effects of phytoestrogens in plant-based aquafeeds on fish growth, reproduction, and sex differentiation

Article Title: Phytoestrogens in aquaculture: friend or foe to fish growth and reproductive health?

Article References: Phytoestrogens in aquaculture: friend or foe to fish growth and reproductive health?. (n.d.). https://doi.org/10.1186/s44315-025-00037-7

Image Credits: AI Generated

DOI: 10.1186/s44315-025-00037-7

Keywords: phytoestrogens, aquaculture, aquafeed, genistein, isoflavones, endocrine disruption, fish reproduction, sex differentiation, vitellogenin, aromatase, soybean meal, fish health

Equol is produced exclusively by gut bacteria from daidzein, one of the principal isoflavones in soy. Unlike its precursor, equol is a selective estrogen receptor-beta agonist with greater antioxidant activity and bioavailability, and it can cross the blood–brain barrier, where laboratory studies suggest it exerts neuroprotective effects against toxin-induced cytotoxicity. The capacity to produce equol, however, is strikingly uneven across the globe: up to 70 percent of East Asians, whose habitual diets are rich in soy, are producers, compared with only 20 to 30 percent of Western populations. This disparity may help explain why randomized trials of soy isoflavones in Europe and the United States have yielded inconsistent results while observational studies in East Asia keep linking equol—not soy isoflavones themselves—to favorable outcomes.

The observational evidence is compelling. Equol producers in East Asian cohorts show lower aortic calcification, reduced risk of coronary heart disease and stroke, lower serum triglycerides, improved endothelial function, and reduced carotid intima-media thickness. Cross-sectional studies have also associated equol production with fewer postmenopausal symptoms and lower risk of mild cognitive impairment. A prospective cohort study in Chinese adults found that producers harbor richer gut microbiota, with enrichment of short-chain fatty acid–producing genera and depletion of inflammation-associated taxa. Taken together, these findings suggest that equol production may be a marker of a broader, functionally favorable gut ecosystem rather than a simple pharmacological trait.

To assess whether that trait can be instilled, the researchers followed PRISMA guidelines and registered their protocol with PROSPERO, searching PubMed, Embase, and Web of Science from the mid-1990s through January 2026. From 503 initial records, screening and full-text review winnowed the field to twelve eligible randomized trials. Eight studies enrolled only women, and six focused exclusively on postmenopausal women. Interventions fell into three broad categories: soy isoflavones alone, soy combined with probiotics or prebiotics, and fermented soy products or other dietary additions such as wheat bran and seaweed. Durations ranged from a single dose over 48 hours to 2.5 years, and eight trials used crossover designs.

The results were uniformly null with respect to conversion. In the isoflavone-only trials, neither ten weeks of high-dose soy nor six months to 2.5 years of supplementation changed producer status. The probiotic and prebiotic trials—most using Lactobacillus acidophilus and Bifidobacterium longum strains, sometimes with fructo-oligosaccharides—likewise failed to convert nonproducers, though two studies hinted that probiotics might enhance equol excretion among women who were already producers. Fermented soymilk converted two of eight participants in one small trial, a trend that did not reach significance, while seaweed combined with isoflavones increased equol secretion in existing producers without changing anyone’s status. Quality assessment using the National Heart, Lung, and Blood Institute tool rated seven trials as fair and five as poor; not one met the criteria for good quality, largely due to missing power calculations and dropout rates exceeding 20 percent in five studies.

The review’s authors argue that these failures reflect the ecological complexity of the gut microbiome rather than biological impossibility. Equol conversion depends on a limited consortium of anaerobic bacteria, notably Slackia isoflavoniconvertens and Adlercreutzia equolifaciens. Crucially, the probiotic strains deployed in the reviewed trials are not equol converters themselves; their beta-glucosidase activity can hydrolyze isoflavone glucosides into aglycones, but they cannot perform the subsequent reductive steps from daidzein to equol. Increasing substrate availability, in other words, accomplishes little when the specialized microbial machinery is absent. Japanese population studies have detected equol-converting bacteria in both producers and nonproducers at comparable levels, indicating that the broader community context—abundance, metabolic activity, and the surrounding microbial network—determines whether conversion actually occurs.

Adding a further complication, equol-producing status may not be a fixed trait. In the Women’s Isoflavone Soy Health trial, 14 percent of postmenopausal and 11 percent of premenopausal participants changed producer status at some point during follow-up, and status crossover occurred even among placebo recipients. A four-year prospective cohort of 498 Japanese adults reported that 26.1 percent of participants had unstable producer status across annual assessments despite comparable daidzein intake. Notably, stable producers exhibited significantly higher gut microbiota diversity and distinct microbial composition compared with both unstable producers and nonproducers, suggesting that only sustained equol production supported by a favorable ecosystem confers the full health benefits. Unstable producers, whose intermediate microbial profiles suggest they may be more amenable to intervention, could represent a key target population for future trials.

Methodological weaknesses compound the problem. Only four of the twelve trials used the standardized three-day soy challenge to establish baseline producer status, and just one applied the reference-standard cutoff of a log-transformed urinary equol/daidzein ratio greater than −1.75. Measurement approaches varied widely, from 24-hour urine collections to overnight urine or serum samples. Ten of the twelve trials were conducted in Western countries, and none included sufficient pre- and post-treatment fecal microbiome analyses—a critical gap that leaves open the question of whether interventions altered microbial community structure even when they failed to induce equol production. The heterogeneity of isoflavone formulations, doses, and delivery routes further obscures whether null results reflect true biological inertness, insufficient bioavailability, or simply inadequate duration.

There are glimmers of promise outside the randomized evidence. Nonrandomized studies suggest that longer-term, higher-dose soy exposure can convert nonproducers: one trial providing one liter of soymilk daily for 16 weeks converted 8 of 20 nonproducers, and vegetarian populations in Western countries produce equol at roughly four times the rate of nonvegetarians, approaching Asian levels—likely because fiber-rich plant-based diets cultivate the fermentative microbial environment the daidzein-to-equol pathway requires. Preclinical work has shown that Slackia isoflavoniconvertens can stably colonize the intestine and convert daidzein to equol in gnotobiotic rat models, providing direct support for prioritizing true equol-converting organisms, potentially paired with prebiotic substrates that selectively sustain them, in future human trials.

The review concludes with a roadmap for the field. Future randomized trials should enroll both sexes across a wide age range, extend intervention durations, employ shotgun metagenomics and targeted quantitative PCR to track equol-converting bacteria, and adopt the standardized urinary equol/daidzein ratio with repeated measurements to avoid misclassification. Trials should also distinguish explicitly among three outcomes—de novo conversion, enhancement of production in existing producers, and stabilization of status in unstable producers. With an ongoing US clinical trial currently testing equol supplementation for cardiovascular and brain health in aging populations, the stakes of getting this right are rising. The authors caution that the negative findings should not be read as proof that conversion is impossible; rather, they reflect the limits of short-term, one-size-fits-all interventions applied to a complex microbial ecosystem. Unlocking equol’s benefits for the majority of Western adults who lack it may require reshaping the gut community itself—a far more ambitious project than simply adding soy to the menu.

Subject of Research: Randomized clinical trials of dietary interventions aimed at converting equol nonproducers to producers through gut microbiome modulation

Article Title: Converting Equol Nonproducers to Producers: A Systematic Review of Randomized Clinical Trials

Article References: Li, J., Li, M., Aboushanab, S., Ebeid, M., Hatanaka, R., Iida, M., Takase, M., Jacobs, I., Gusmanov, A., Hirata, A., Miyagawa, N., Nakaya, N., Sugiyama, D., Tilves, C., Hozawa, A., Li, X., Mueller, N. T., Benos, P. V., & Sekikawa, A. (2026). Converting Equol Nonproducers to Producers: A Systematic Review of Randomized Clinical Trials. Food Science & Nutrition, 14(10), Article e72394. https://doi.org/10.1002/fsn3.72394

Image Credits: AI Generated

DOI: 10.1002/fsn3.72394

Keywords: equol, soy isoflavones, daidzein, gut microbiome, systematic review, randomized clinical trials, probiotics, prebiotics, menopause, cardiovascular health, phytoestrogens, nutrition